Is Myriad hoarding patient data?

Myriad Genetics is perhaps best known for its ultimately failed defence of its patents on the BRCA1 and BRCA2 genes associated with elevated risk of breast cancer.  

A new article describes another way in which the company has offended some cancer patients, namely by keeping details of their test results a proprietary secret.  

Blog topics

  1. 2018 (17)
    1. December (2)
    2. October (2)
    3. August (2)
    4. July (3)
    5. June (3)
    6. May (2)
    7. March (2)
    8. January (1)
  2. 2017 (44)
    1. December (1)
    2. August (3)
    3. July (4)
    4. June (6)
    5. May (5)
    6. April (3)
    7. March (6)
    8. February (8)
    9. January (8)
  3. 2016 (95)
    1. December (7)
    2. November (13)
    3. October (13)
    4. September (15)
    5. August (20)
    6. July (18)
    7. June (9)